Follow Us

diabetes FDA

A friend of mine in the Diabetes Community recently mentioned being burnt out on advocacy.
So many great diabetes causes and efforts, but just so many Asks at the moment… with this being the start of November, national Diabetes Awareness Month.
This D-peep is a longtime type 1 from my local community, someone who’s been very active offline through the years and has generally jumped at the chance to raise awareness and deepen connections with…

From our friends at diaTribe: On November 3, the FDA will host an unprecedented discussion between the diabetes community and senior agency leadership (on both drugs and devices). The event will be live webcast from 1-4 pm Eastern. We want this to be nothing short of a home run.
We at the ‘Mine are thrilled to see this kind of direct patient community interaction with FDA coming to fruition, and want to encourage you all…

As you may know, our correspondent Wil Dubois was on the ground in Orlando, FL, covering the big annual American Association of Diabetes Educators (AADE) meeting for us last week.
Check out his first Newsflash on Asante and Insulet stuff from last Friday. And now, we bring you his full report of product news from the trade show floor…

It must have been the heat and humidity. After all, AADE chose to host their annual…

It’s official: Tandem Diabetes Care has made its filing with the U.S. FDA for an integrated insulin pump and continuous glucose monitor — a new device that combines their sexy t:slim touchscreen pump with a Dexcom G4 Platinum CGM.
News of the FDA filing came out publicly during the company’s 2nd quarter earnings call held this past Thursday (July 31), in which San Diego, CA-based Tandem reported on its current financial standing. The big news…

Big News this week in the world of diabetes devices, Folks!
Two leading endocrinologist organizations have, for the first time in four years, updated their position on who should be able to get access to insulin pumps, while the Diabetes Technology Society (DTS) is launching a post-market surveillance program aimed at ensuring glucose meters and test strips are accurate even long after they’re cleared FDA and are in the hands of people with diabetes.
Both…